Are you affected by
systemic sclerosis?

If you or a loved one are living with systemic sclerosis (scleroderma or SSc), consider joining the TibuSURE clinical study where researchers are exploring
the effect of a study drug on disease progression
in individuals with systemic sclerosis.

I'm interested

What is the Purpose of the TibuSURE Study?

The goal of this study is to evaluate the safety and effectiveness of tibulizumab on certain scleroderma signs and symptoms.

You may also know systemic sclerosis by these other terms: scleroderma or SSc
Click Here to Express Interest

Can I Participate?

You may be eligible to participate in this study if you:

I'm Interested

Are between 18 and 70 years old

Have a confirmed diagnosis of systemic sclerosis impacting your extremities (for example: arms, legs, hands, feet, etc.)

Have experienced symptoms related to your systemic sclerosis for less than 5 years (apart from Raynaud’s)

Why Should I Join the TibuSURE Study?

By enrolling in this Phase 2 study, you may participate in a clinical study working to evaluate the effect of a study drug on disease activity in skin thickening and lung function.

‍Other eligibility criteria apply and will be evaluated by a study doctor if you choose to continue with screening for the study.

I'm Interested
Uncertainty related to scleroderma is hard;
learning about a clinical trial opportunity shouldn't be
Learn more about this clinical study opportunity.

By enrolling in this Phase 2 study, you may receive:

Travel and accommodation support for study visits

Click Here to Express Interest  
Learn More

What Should I Expect?

Step 1
Submit Online Questionnaire
This questionnaire will ask for your contact information and a few questions about your medical history to determine your eligibility. Then, select a time for a short phone call with PatientWing.

Submitting the questionnaire is voluntary and does not require a commitment to participate in the study.

Step 2
Speak With PatientWing
PatientWing is partnering with Zura Bio to help identify potential individuals who may be interested and qualify for the TibuSURE study.  You will have a short call to answer additional questions about your medical history and determine whether you might be a potential participant for the study.
Step 3
Speak With a Research Site
After your conversation with PatientWing, you may meet the research team who will review your medical records.  If the research team thinks you are a good fit, they will schedule a screening visit. The research team will provide more information during your conversation with them.

No question is a bad question so please share your concerns with the team! 
Step 4
Study Participation
‍After you've completed the screening activities, the research team will notify you about your eligibility to continue as a study participant and potentially receive drug as part of the trial. If you continue in the study after being confirmed as eligible, you should expect the following:

• You will visit the study site 17 times over approximately 1 year and 4 months.
‍• You will be given 2 injections at the study site once every two weeks for the first month and then every four weeks thereafter.
• If eligible, you may receive travel and accommodation support for study visits.  

Frequently Asked Questions

How do I get started?
Click "I'm Interested" and enter your information to express interest in the study. You can also email studies@patientwing.com.
How often do I need to visit the research site?  
If you qualify for the study and choose to participate, you will have visits every 4 weeks for 17 visits, with the exception of a visit 2 weeks after the first dose and the final visit.
Are there possible benefits of participating?
By participating in this study you can contribute to  a better understanding of SSc. The data obtained from you during this study may help doctors learn more about the potential effects of tibulizumab in patients with SSc
How long will the study take?
The study takes about 1 year and 6 months from the start of the screening activities to the follow-up visit. 
How will the study drug be taken?
If you qualify for the study and choose to participate, you will be given an injection under the skin every two weeks for the first month and then every four weeks after.

Who's Involved?

Option Item Img
Zura Bio is focused on developing novel and transformative solutions to address the challenges posed by the heterogeneity of autoimmune diseases.
Option Item Img
Our mission to bring better treatments to more people faster starts with you. We help sponsors find patients to participate in their clinical studies. With our focus on rare and serious conditions and expertise in navigating the enrollment process, we're here for you every step of the way.

Stay Connected

Receive marketing communications from PatientWing such as patient stories and relevant clinical trial opportunities.
By clicking subscribe, you consent to PatientWing contacting you in accordance with their Privacy Policy. You will be able to unsubscribe from PatientWing communications at any time.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Have Questions?

At PatientWing, we’re here to support you at every step of the study. You can email or fill out the form with any questions. We’re here to help.
Call Us
+44 0121 468-3076
Email Us
studies@patientwing.com
By clicking submit, you consent to sharing your personal data, including personal health information, with PatientWing and allowing PatientWing to collect this information and use it to contact you and respond as appropriate to your inquiry.  Please note that PatientWing will not sell your personal information or share it with third parties for marketing purposes.  For additional information on how PatientWing stores and processes personal data, please review their Privacy Policy. You will be able to unsubscribe from PatientWing communications and/or request that your information be deleted at any time.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Tibulizumab is an investigational agent, meaning that its efficacy and safety have not been established by any regulatory agency worldwide.
A clinical study for people with scleroderma.
Can I Participate?What To ExpectFrequently Asked QuestionsContact Us
© Copyright 2025 Powered by PatientWing
Privacy PolicyTerms & Conditions